Synairgen’s (SNG) “Corporate” Rating Reaffirmed at FinnCap

FinnCap restated their corporate rating on shares of Synairgen (LON:SNG) in a research report sent to investors on Thursday.

Shares of Synairgen stock opened at GBX 15.50 ($0.20) on Thursday. Synairgen has a 1 year low of GBX 6.88 ($0.09) and a 1 year high of GBX 32 ($0.42).

Synairgen Company Profile

Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-ß that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

See Also: Investing strategies using the yield curve

Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit